and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European ...

Learn More CSL Ltd (ASX: CSL) shares are up 0.3% at $261.87 today, shaking off the broader market sell-down. This sees the company with a market cap of almost $127 billion, making it the third ...

In terms of its build and components, the 2800 also uses higher density feet than the 1700, as well as a larger power supply and capacitors. The front panel includes a USB port for a mass storage ...

Pin the throttle to the carpet in the BMW M4 CS, and it’s hardly the blink of an eye before an explosive wave of thrust and sound hurtles you towards the horizon while squeezing the air from your ...

CSL Limited (CSL), an ASX-listed company, is a global biotechnology company engaged in research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines. CSL's ...

While otherwise robust, CSL half-year results last Wednesday revealed the impact of an “alarming” fall off in influenza vaccination rates, especially in the US. CEO Paul McKenzie attributes the ...

Last November, I strapped into the rear passenger seat of an all-electric, four-door sedan with BMW test driver and 24-hour racer Jens Klingmann behind the wheel. It was a cold day at BMW’s ...

The GHP-2800 is the first GOMACO paver to use CAN-based G+ Connect networking that speeds two-way communication between accessories and G+ paver controller GOMACO says the electric-over-hydraulic ...

CSL Limited (ASX:CSL) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to AU$257 in the week after its latest half-year results. Revenues of US$8.5b were in line ...

CSL has a portfolio that includes treatments for haemophilia and immune deficiencies, and influenza vaccines. Credit: © 2023 CSL, All Rights Reserved. CSL has ...

ASX health stocks fell 3.78% over the past week, while the broader market edged up 0.77% Australia’s biggest health care name CSL weighed on sector with soft H1 FY25 result Shares of merged Chemist ...

CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market expectations Behring and Vifor outperformed, while Seqirus underperformed due to ...